Supplementary Tables 1-2 from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
David T. Miyamoto(Broad Institute), Daniel A. Haber(Howard Hughes Medical Institute), Richard J. Lee(La Roche College), Chin‐Lee Wu(Massachusetts General Hospital), Brian W. Brannigan(Harvard University), Malgorzata E. Smas(Harvard University), Ben S. Wittner(Broad Institute), Shyamala Maheswaran(Massachusetts General Hospital), Neil H. Bander(Convergent Science (United States)), Shannon L. Stott(Shriners Hospitals for Children - Erie), Lecia V. Sequist(Harvard University), Julie Trautwein(Harvard University), Mehmet Toner(Center for Cancer Research), Jenna B. Lord(Harvard University), Matthew R. Smith, Matthew Ulman(Harvard University), Sridhar Ramaswamy(Harvard University), David T. Ting(Massachusetts General Hospital)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
|Cell|2004|3.8k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k